ABSTRACT
Background Insomnia is common and causes immense disease burdens for society. Current sleep medications show suboptimal clinical features, leaving an unmet need for pharmacological innovation to improve both sleep and waking functions. The locus coeruleus noradrenergic (LC-NA) system may provide a potential new target for pharmacological insomnia treatment, particularly in patients with elevated stress. The selective α2 noradrenergic agonist dexmedetomidine (DEX) attenuates LC-NA activity. In current use as intravenous anesthetic, DEX could thus be a promising repurposing candidate for stress-related insomnia.
Methods We developed two distinct, fast-disintegrating, oro-mucosal - one sublingual and one buccal - DEX formulas tailored for self-administration and established their pharmacokinetic and pharmacodynamic (PK-PD) profiles. In two separate studies, the first comprising 8 healthy male good sleepers and the second including 17 men with subclinical insomnia, we administered sub-anesthetic doses (20 & 40 µg) of the two formulas. Both studies followed a randomized, double-blind, placebo- controlled, cross-over design. We complemented the PK assessments during sleep by all-night polysomnography, nocturnal cortisol and melatonin measurements, assessments of cardiovascular functions during and after sleep, cortisol awakening response, and examination of post-awakening subjective state and vigilance.
Results Particularly buccal DEX was rapidly absorbed and exhibited excellent dose-proportionality with minimal between-subject variation in exposure. Additionally, DEX shortened the latency to fall asleep, increased the time spent in non-rapid-eye-movement (NREM) sleep, and elevated electroencephalographic slow wave energy (0.75-4.0 Hz), a marker of NREM sleep depth. Rapid-eye- movement (REM) sleep latency was dose-dependently prolonged. Nocturnal cortisol, melatonin and heart rate, as well as morning cortisol, were not significantly affected by DEX nor did post-awakening orthostatic regulation, subjective sleepiness and mood, and psychomotor vigilance differ among the conditions.
Conclusions The favorable PK-PD profile of oro-mucosal delivery of sub-anesthetic DEX doses warrants further dose-finding and clinical studies, to establish the exact roles of the LA-NA system in pharmacological sleep enhancement and α2 receptor agonism as novel mode of action in alleviating stress-related insomnia.
Competing Interest Statement
Rafael Wespi, MSc, Dario A. Dornbierer, PhD, and Hans-Peter Landolt, PhD are listed as inventors on a pending patent on "Dexmedetomidine for the treatment of sleep disorders" (UniTectra Fall-Nr. UZ 231534a) that is assigned to University of Zurich, Zurich, Switzerland. Further, Dario A. Dornbierer, PhD, declares that he co-founded Reconnect Labs, an academic spin-off company of the University of Zurich, focused on the development of dexmedetomidine-based products for the treatment of sleep disorders.
Clinical Trial
ClinicalTrials.gov: Identifier # NCT04508166
Funding Statement
This work was supported by InnoSuisse (grant # 55588.1 INNO-LS), the European Research Council (AdG grant # 101055383), the Wellcome Trust (grant # 227100/Z/23/Z) and institutional funds.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study procedures were reviewed and approved by the Cantonal Ethics Committee of the Canton of Zurich (BASEC # 2020-016114). All participants provided written informed consent according to the declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available after peer-reviewed publication upon reasonable request to the authors.
